Background: Evidence has demonstrated that overproduction of prostacyclin (PGI 2 ) is critical in the pathogenesis of splanchnic hyposensitivity to vasoconstrictors in the cirrhotic state. The biosynthesis of PGI 2 is through cyclooxygenase (COX). This study evaluated which isoform of COX is dominant in the mechanism of collateral vascular reactivity of biliary cirrhotic rats. Methods: Three groups of formalin-injected common bile duct-ligated (FBDL) induced cirrhotic rats received two doses of: (1) selective COX-1 inhibitor (SC-560 2 mg/kg); (2) COX-2 inhibitor (NS-398 2 mg/kg); (3) dimethyl sulfoxide (control). Subsequently, the rats were kept in metabolic cages for 24 hours to collect urine. Thereafter, the systemic and portal hemodynamics and renal function were measured. In another series, using in-situ collateral perfusion model, the collateral vascular responses to arginine vasopressin (AVP) were measured in the subject rats after preincubation of vehicle (Krebs solution), SC-560 (5 mM) or NS-398 (10 mM). Results: The mean arterial pressure, heart rate, and portal pressure were similar among SC-560-treated, NS-398-treated, and control groups. Additionally, there was no significant difference in the calculated creatinine clearance rates among these three groups. SC-560 preincubation significantly enhanced the pressor effect of AVP at the concentration of 3M Â 10 À9 M (11.0 AE 1.0 mmHg vs. 6.4 AE 0.6 mmHg, p ¼ 0.002) in the cirrhotic rats. Conclusion: There was no significant hemodynamic change and renal toxicity after acute administration of COX inhibitor in the FBDL-induced cirrhotic rats. Preincubation of selective COX-1, but not COX-2, inhibitor could enhance collateral vascular response to AVP, indicating that COX-1 plays a major role in the collateral vascular reactivity.
Introduction
The portalesystemic collateral vasculatures elicit many severe complications in cirrhotic patients. As the portal pressure elevates, abundant collaterals develop gradually to divert blood flow from the portal system and induce disastrous gastroesophageal varices. 1 Excessive production of nitric oxide (NO) and prostacyclin (PGI 2 ) induce hyperdynamic circulation in cirrhotic patients. 2, 3 Overproduction of vasodilatory NO and PGI 2 blunts the splanchnic vascular response to endogenous vasoconstrictors. 4 The decreased collateral vascular reactivity has clinical relevance because it would attenuate the hemostatic effect of vasopressin during acute variceal bleeding. PGI 2 is a vasodilatory substance capable of increasing portal tributary blood flow that has been well-documented to participate in the mechanism of hyperdynamic circulation in cirrhotic patients. 5 It also attenuates the response of vasopressin in splanchnic and portal-systemic collaterals in portal hypertensive status. 6, 7 The biosynthesis of PGI 2 is through cyclooxygenase (COX). Using nonselective COX inhibition by indomethacin administration, we have successfully documented that blockade of PGI 2 could enhance the vasoconstrictive effect of glypressin and improve splanchnic hyposensitivity in both portal hypertensive and cirrhotic rats. 8, 9 In addition, chronic administrations of indomethacin can enhanced collateral vascular response to vasopressin in cirrhotic rats. 10 COX is the key enzyme of prostanoid biosynthesis. It is well known that COX exists in at least two different isoforms: COX-1 and COX-2. A previous study provided evidence of the involvement of both COX-1 and COX-2 metabolites in splanchnic hyposensitivity in portal hypertensive rats. 11 However, which isoform of COX undertakes the primary role in the mechanism of splanchnic hyposensitivity is still debated. Potenza et al 11 demonstrated that the generation of endothelial vasodilatory prostanoids, primarily from COX-2, accounts for the increased mesenteric blood flow in portal hypertensive rats. In addition, Blanco-Rivero et al 12 also reported that COX-2 derivative PGI 2 does participate in the hyperdynamic circulation of portal hypertensive rats. However, in portal hypertensive rats with acute hemorrhage, we found that COX-1 mRNA is overexpressed in the superior mesenteric artery, which implies that COX-1, but not COX-2, played a key role in mediating the splanchnic hyposensitivity. 13 Therefore, which isoform of COX enzyme takes on the primary role in vascular reactivity of the portalesystemic collateral remains to be clarified.
Regarding cirrhotic patients, the adverse effect of the COX inhibitor on renal function is also of concern. In cirrhotic patients, nonselective COX inhibition by indomethacin greatly impairs renal plasma flow, creatinine clearance rate, and serum creatinine levels.
14 However, selective COX-2 inhibition seems promising because it does not significantly impair renal function in cirrhotic rats. 15 There has been some evidence suggesting that nonselective and selective COX inhibitors appear to have similar adverse effects on renal function, if dosed equivalently, which is particularly significant in patients with congestive heart failure and liver cirrhosis. 16 Therefore, it would be worthwhile to investigate the impact of administering selective COX-1 and COX-2 inhibitors on renal toxicity in cirrhotic state.
Therefore, using an in situ collateral vascular perfusion model of biliary cirrhotic rats, this study assessed the effects of selective COX-1 and COX-2 inhibitors on: (1) hemodynamics and renal function, and (2) collateral vascular responsiveness to arginine vasopressin (AVP) in cirrhotic rats.
Methods

Animal model
Male SpragueeDawley rats weighing 240e270 g at the time of surgery were used in this experiment. The rats were housed in plastic cages and allowed free access to food and water. All rats were fasted for 12 hours prior to the operation. All animals received humane care according to the criteria outlined in the Guide for the Care and Use of Laboratory Animals prepared by the National Academy of Sciences and published by the National Institutes of Health, USA (NIH Publication No. 86-23, revised 1985) . Rats with secondary biliary cirrhosis were induced with common bile duct ligation followed by injecting formalin into the biliary tree (FBDL). A high yield of secondary biliary cirrhosis was noted 4e6 weeks after the ligation. 17 To avoid coagulation defects, FBDL rats received weekly vitamin K injection (50 mg/kg intramuscularly). . 15 Subsequently, the rats were kept in metabolic cages for 24 hours for the purpose of urine collection. The second injections of the same drugs or DMSO were administered 12 hours after they were in the metabolic cages. Twenty-four hours later, rats were anesthetized with ketamine hydrochloride (100 mg/kg intramuscularly) and the body weight, mean arterial pressure, portal pressure, and heart rate were measured. The serum creatinine, urine volume, and urine creatinine of different groups were also measured.
Experiment 2: effects of selective COX inhibition on collateral vascular responsiveness to AVP
The collateral perfusion studies with preincubation of vehicle (Krebs solution, n ¼ 10), selective COX-1 inhibitor (SC-560; 5 mM, n ¼ 8) or selective COX-2 inhibitor (NS-398; 10 mM, n ¼ 7) were conducted via in situ collateral vascular perfusion model in cirrhotic rats. The body weight, mean arterial pressure, portal pressure, and heart rate were measured before the perfusion study. The cumulative concentrationeresponse curves of collateral vessels were determined by graded final concentrations of AVP in escalation with a constant flow rate (12 mL/minute). The final concentrations of AVP in the perfusate ranged from 10 À10 M to 10 À7 M. Each new concentration was allowed to stabilize for 3 minutes prior to adding the next higher concentration.
Measurement of systemic and portal hemodynamics and renal function
The right femoral artery of FBDL rats was cannulated with a PE-50 catheter that was connected to a Spectramed DTX transducer (Spectramed Inc., Oxnard, CA, USA). Continuous recordings of mean arterial pressure and heart rate were taken by use of a multi-channel recorder (Model RS 3400; Gould Inc., Cupertino, CA, USA). The external zero reference was placed at the level of the mid-portion of the rat. The abdomen was then opened with a mid-line incision, and a mesenteric vein was cannulated with a PE-50 catheter connected to a Spectramed DTX transducer. The abdominal cavity was closed and portal pressure was recorded on a Gould Model RS (Gould Inc., Cupertino, CA, USA) 3400 recorder. Blood sampling was taken for serum creatinine measurement. A 3 mL blood sample was collected into a pyrogen-free syringe containing w75 units of heparin sodium, then placed in an ice bath and transported immediately to the laboratory. Serum was separated in a refrigerated centrifuge at 4 C and 3000 rpm for 10 minutes. The levels of serum creatinine and urine creatinine were measured by Vitro DT chemistry system (Johnson & Johnson, Inc, New York, NY, USA). The amount of urine and water intake over a 24-hour period for each experimental group was recorded. The 24-hour creatinine clearance rate was calculated from the following formula: creatinine clearance rate (mL/minute) ¼ 24-hour urine volume (mL) Â urine creatinine concentration (mg/ dL)/1440 (minutes) Â serum creatinine concentration (mg/dL), indicating the assessment of renal function.
In-situ perfusion preparation
The in-situ perfusion system was performed as previously described with minor modifications. 7, 18 In brief, both jugular veins were cannulated with 16-gauge Teflon cannulas to ensure an adequate outflow without any resistance even at the highest flow rates. Heparin (200 U/100 g body weight) was injected through one of the cannulas. The abdomen was then opened and an 18-gauge Teflon cannula was inserted in the distal superior mesenteric vein and fixed with cyanoacrylate glue. To exclude the liver from perfusion, the portal vein was ligated. The animal was transferred into the compartment of a warm chamber (37 AE 0.5 C). The temperature around the perfusion area was continuously monitored with a thermometer placed inside the mesenteric artery and maintained at approximately 37 AE 0.5 C with a thermostatic pad and temperature-controlled infrared lamp. An open circuit perfusion then was started with Krebs solution (composition: NaCl, 118 mM; KCl, 4.7 mM; KH 2 PO 4 , 1.2 mM; MgSO 4 , 1.2 mN; CaCl 2 , 2.5 mM; NaHCO 3 , 25 mM; dextrose, 11.0 mM; pH, 7.4; 37 AE 0.5 C) via the mesenteric cannula by a roller pump (Model 505S; Watson-Marlow Limited, Falmouth, Cornwall, UK). The perfusate was equilibrated with carbogen gas (95% O 2 , 5% CO 2 ) by a silastic membrane lung. Both jugular vein cannulas were simultaneously opened to allow a complete washout of the blood. Pneumothorax was created by opening slits through the diaphragm to increase resistance in pulmonary arteries and prevent the perfusate from entering the left heart chambers. The collaterals were then perfused with oxygenated (95% O 2 , 5% CO 2 ) Krebs solution containing 3% wt/vol albumin (factor V bovine serum albumin; Sigma Chemical Co., St Louis, MO, USA). The effluent of the perfused fluid was not recirculated. To monitor and record the pressure in the portal-systemic collaterals continuously, a Spectramed DTX transducer attached to the Gould Model RS (Gould Inc., Cupertino, CA, USA) 3400 recorder was connected to a side arm placed just proximal to the perfusion cannula, with the zero placed at the level of right atrium. Because the temperature and pressure of the system were stabilized within 20 minutes, all experiments were performed 25 minutes after starting perfusion at a constant rate of 12 mL/ minute. Moreover, the perfusion flow rate was kept constant throughout the entire experiment, so the changes in perfusion pressure reflected the changes in collateral vascular resistance. Only one concentrationeresponse curve was performed in each preparation. In each individual preparation, after testing experimental agents, the contracting capability of the portalesystemic collateral vessels was challenged with a 125-mmol/L potassium chloride solution at the end of experiment.
Drugs
SC-560, NS-398, the reagents for preparing Krebs solution and AVP were purchased from Sigma Chemical Co. All solutions were freshly prepared on the day of experiment.
Data analysis
All results are expressed as mean AE standard error of the mean. The change in perfusion pressure (mmHg) over baseline was calculated for each concentration in each preparation. Statistical analyses were performed using one-way analysis of variance (ANOVA). The normality assumption was tested prior to doing one-way ANOVA analysis. Furthermore, the nonparametric method was also performed. Results were considered statistically significant at a two-tailed p < 0.05.
Results
3.1. Experiment 1: hemodynamic effects and renal function after selective COX-1, COX-2 inhibitor treatment Table 1 shows the body weights, baseline hemodynamic parameters, and portal pressures after injections of COX-1 inhibitor SC-560, COX-2 inhibitor NS-398, and DMSO (control) in FBDL rats. The mean arterial pressure, heart rates and portal pressure were similar among SC-560-treated, NS-398-treated, and control groups. Decreased urine amounts were observed in SC-560-treated rats compared to the NS-398-treated and control groups (control: 32 AE 3.3 mL/day; SC-560: 25 AE 1.3 mL/day; NS-398: 36 AE 2.6 mL/day; p ¼ 0.02, Fig. 1A ). The 24-hour water intakes of these three groups had no significant differences (Fig. 1B) . The increased concentrations of urine creatinine were noted in SC-560-treated group compared to the other two groups (control: 38 AE 5.1 mg/dL; SC-560: 50 AE 3.6 mg/dL; NS-398: 32 AE 2.8 mg/dL; p ¼ 0.03, Fig. 2A) . The serum creatinine levels and calculated 24-hour creatinine clearances rates did not have significant differences among these three groups (Fig. 2B and C) . Table 2 shows baseline hemodynamic parameters and body weights of FBDL rats prior to the SC-560, NS-398, and vehicle preincubation in the perfusate. The body weights, mean arterial pressure, heart rates, portal pressure, and baseline perfusion pressure were similar among these three groups. Fig. 3 depicts the concentrationeresponse curves obtained at a constant perfusion flow rate by the cumulative addition of AVP into the perfusate of three groups. Preincubation of SC-560, but not NS-398, enhanced the pressor effects of AVP compared to control group. The maximal perfusion pressure change occurred at the concentration of 3M Â 10 À9 M in SC-560 preincubation group (SC-560 11.0 AE 1.0 mmHg; control: 6.4 AE 0.6 mmHg, p ¼ 0.002, Fig. 3 ). 
Experiment 2: collateral vascular responsiveness to AVP with selective COX-1 or COX-2 inhibitor preincubation
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Discussion
In the present study, we have demonstrated that preincubation of selective COX-1 inhibitor SC-560 could enhance collateral vascular response to AVP. This result indicates that COX-1, but not COX-2, plays a major role in the vascular reactivity of portalesystemic collaterals. Consistent with a prior study, acute administration of selective COX-1 and COX-2 inhibitors did not influence systemic arterial and portal pressures. 10, 19 The influence of COX inhibition comes from alteration of splanchnic and collateral vascular response, without having a direct effect on systemic arterial and portal pressure. In addition, acute injection of selective COX-1 or COX-2 inhibitors did not impair the renal function in cirrhotic rats, which was made evident by similar creatinine clearance rates among COX-1-treated, COX-2-treated, and control groups. Taken together, our data suggest that acute administration of COX-1 inhibitor can improve collateral vascular reactivity of cirrhotic rats without obviously detrimental effects on renal function and hemodynamics.
Although COX-2 is usually sought as an inducible isoform, it is constitutively expressed in the kidney. 20 There is concern about whether selective COX inhibition induces renal vasoconstriction and decreases renal plasma flow, further impairing the renal function. Bosch-Marcè et al 15 documented that the selective COX-2 inhibitor SC-236 did not significantly impair renal function in rats with CCl 4 -induced cirrhotic rats. However, Qi et al 21 have reported that acute infusion of COX-2 inhibitors could reduce renal medullary blood flow and decrease urine flow in normal mice; by contrast, COX-1 inhibitor did not affect renal cortical and medullary blood flow. Interestingly, they also found that COX-1 inhibition would unexpectedly blunt the pressor effect of angiotensin II through enhancement of renal medullary PGI 2 ; however, COX-2 inhibition augmented the vasoconstrictive effects of angiotensin II. Therefore, they concluded that selective COX-1 and COX-2 inhibition had opposite effects on the pressor response to angiotensin II, and a different impact on renal blood flow. In the present study, urine amounts were significantly decreased after SC-560 treatment but the compensated concentration of urine creatinine resulted in calculated creatinine clearance rates that were similar between treated and control groups. We did not measure the renal plasma flow of cirrhotic rats and could not determine the effect of acute administration of COX inhibitor on the blood flow change of the kidney. It is generally understood that clearance rate of creatinine is an indicator for the quality of renal function. Therefore, the present data reveal that short-term administration of COX inhibitor does not impair renal function of cirrhotic rats. Nevertheless, the longterm effects of selective COX-1 and COX-2 inhibition on the kidneys of cirrhotic status require further investigation.
The therapeutic utility of COX inhibitors as antiinflammatory agents comes from the inhibition of COX-2, whereas inhibition of COX-1 may cause unwanted gastric and renal toxicities. In cirrhotic patients, nonselective COX inhibition increases the incidence of portal hypertensive gastropathy and renal function deterioration. 22, 23 Thus, the selective COX-2 inhibitor is a potential drug of choice for cirrhotic patients to address anti-inflammation and analgesia. However, the selective COX-2 inhibitor has an important restraint due to its cardiovascular adverse effects. The issue of cardiovascular risk caused by selective COX-2 inhibitor does merit concern. Both the APPROVe study and the APC trial demonstrated that selective COX-2 inhibitors increase the risk of myocardial infarction in a dosage-and duration-dependent manner. 24, 25 In fact, both selective and nonselective COX inhibitors have potentially adverse effects on the cardiovascular system. Moncada et al 26 have even stated that a balance between the amounts of thromboxane A2 formed by platelets and PGI 2 formed by vessels might be critical for thrombus formation. The COX inhibitors may be harmful in the cardiovascular system by blocking PGI 2 biosynthesis without affecting thromboxane production. 27 In the present study, COX-1, but not COX-2, inhibitor SC-560 significantly enhanced the pressor effects of AVP in the collateral vessels. Although both COX-1 and COX-2 blockade can decrease plasma PGI 2 levels, we have demonstrated that administration of SC-560 is more capable of abolishing PGI 2 than NS-398 in fulminant hepatic failure rats. 28 The different capacity to blockade PGI 2 may explain that preincubation of SC-560, but not NS-398, significantly enhances collateral vascular response to AVP in cirrhotic rats. This also implies that COX-1 Fig. 3 . Concentrationeresponse curves to arginine vasopressin in the collateral vessels of cirrhotic rats with preincubation of vehicle (Krebs solution), SC-560, and NS-398. In the SC-560 preincubation group, the perfusion pressure is significantly higher as compared with the control group (*p ¼ 0.002).
plays a more important role against pressor effects in the collateral vessels of cirrhotic rats.
There are some conflicting reports about COX-1 and COX-2 differentially affected reactivity of vessels in portal hypertensive rats. Pontenza et al 11 demonstrated that exposure of mesenteric vascular bed to indomethacin, SC-560, or NS-398 reversed the hyporeactivity to norepinephrine in portal hypertensive rats, with the selective COX-2 inhibitor NS-398 being more potent than the others. On the contrary, Graupera et al 29 demonstrated that sinusoidal endothelial COX-1-derived prostanoids modulate the hepatic vascular tone of cirrhotic rat liver. They found that the increased response to pressor effects of methoxamine in cirrhotic liver is mainly dependent of COX-1 despite abundant hepatic COX-2 expressions. These diverse reports about the dominant role of COX-1 or COX-2 as an influence on pressor effects may be due to different animal models and vascular territories including collateral vessels, intrahepatic vasculature or superior mesenteric artery.
Because of the concern about cardiovascular events of selective COX-2 inhibitor, the role of selective COX-1 blocker as a therapeutic agent elicits substantial discussion. We have demonstrated that COX-1 inhibition by SC-560 decreased mortality and improved hepatic encephalopathy in fulminant hepatic failure rats. 28 In the present study, we found that acute administration of selective COX-1 inhibitor, but not COX-2 inhibitor, can augment the vasoconstrictive effect of AVP without deteriorating the renal function. In addition, our previous report documented that chronic administration of nonselective COX inhibitor could enhance the pressor effects of AVP without increasing collateral shunting degrees in cirrhotic rats. 10 These data suggest that inhibition of COX, especially using selective COX-1 inhibitors, can improve collateral vascular reactivity of biliary cirrhotic rats. Nonetheless, the COX inhibitors still have many adverse effects including gastric mucosal damage and potential renal toxicity. Prior evidence has shown that selective COX-1 inhibition by SC-560 dosedependently caused gastric mucosal damage in portal hypertensive rats. 30 Therefore, any translational value may be limited by complex hemodynamic change and possible complications of cirrhotic patients. We should be cautious in efforts to extrapolate the results of animal studies to human patients.
In conclusion, this study demonstrated that acute administration of selective COX-1 and COX-2 inhibitors do not significantly impair renal function or alter systemic hemodynamics and portal pressures of FBDL-induced cirrhotic rats. Selective inhibition of COX-1, but not of COX-2, obviously enhances the collateral vascular response to AVP, which implies that collateral vascular hyposensitivity of cirrhotic rats has improved.
